The key catalyst is the January 21, 2027 PDUFA date for z-rostudirsen; approval would mark Dyne's first commercial product. The wider net loss and increased spending on manufacturing and Phase 3 trials are expected for a pre-commercial biotech. Monitor the ACHIEVE REC topline data in Q1 2027 for z-basivarsen as the next major pipeline catalyst.
Drugs in focus
DYN drug pipeline →z-rostudirsen
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
- Time to market
- Potential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).
- Next catalyst
- PDUFA date · Jan 21, 2027 65d
What to watchThe January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.
Price Chart
Executive Summary
The BLA for z-rostudirsen in DMD is under FDA priority review with a PDUFA date of January 21, 2027, and topline data from the ACHIEVE REC for z-basivarsen in DM1 is expected in Q1 2027. Cash of $1.134B is expected to fund operations into Q2 2028.
Key Facts
- Cash, cash equivalents and marketable securities of $1.134B as of September 30, 2026, sufficient into Q2 2028
- BLA for z-rostudirsen (exon 51 DMD) under FDA priority review with PDUFA target action date of January 21, 2027
- Topline data from ACHIEVE registrational expansion cohort for z-basivarsen (DM1) planned for Q1 2027
- R&D expenses increased to $161.7M from $97.2M YoY, driven by manufacturing and Phase 3 trial costs
- G&A expenses increased to $35.3M from $16.7M YoY due to launch preparation and headcount growth
Financial Impact
Net loss of $193.6M in Q3 2026, $85.6M wider than Q3 2025; cash burn rate increased significantly
Risk Factors
- FDA may not approve z-rostudirsen by the PDUFA date or may require additional data
- Z-basivarsen ACHIEVE REC topline data in Q1 2027 may not support BLA submission
- Cash burn rate is accelerating; $1.134B may not be sufficient if timelines slip or additional trials are needed
- Competing therapies for DMD and DM1 could limit commercial potential if approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001818794-26-000013 |
| Document: dyn-20261105.htm | 0001818794-26-000013 |
| Document: 0001818794-26-000013-index-headers.html | 0001818794-26-000013 |
| Document: 0001818794-26-000013-index.html | 0001818794-26-000013 |
| Document: 0001818794-26-000013.txt | 0001818794-26-000013 |
| 8-K Data (Synthetic) | 0001818794-26-000013 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers